GSK gets FDA nod for Shingrix to prevent shingles in immunocompromised adults
Shingrix is a non-live, recombinant sub-unit adjuvanted vaccine, administered intramuscularly in two doses
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Jul 21
Shingrix is a non-live, recombinant sub-unit adjuvanted vaccine, administered intramuscularly in two doses
27 Jul 21
The acquisition of BioLegend, the largest transaction in PerkinElmer’s history, will expand its existing life science franchise into…
26 Jul 21
Spikevax produced similar level of antibodies in children aged 12 to 17 years, to that observed in young…
26 Jul 21
It is the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the indicated…
23 Jul 21
We look at how, according to industry experts, professionals can look to guidance from the FDA to improve…
23 Jul 21
ARV-471 is currently in Phase 2 studies for the treatment of patients with locally advanced or metastatic ER+/HER2-…
23 Jul 21
The jury found that the Novartis failed to prove that patents were invalid and concluded that the infringement…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Jul 21
Pfizer and BioNTech will immediately start technical transfer, on-site development and equipment installation activities
22 Jul 21
With the acquisition, AstraZeneca now has an enhanced presence in rare diseases and immunology fields, using Alexion’s complement-biology…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Jul 21
The US FDA approval of Octagam is based on positive data from the Phase 3 ProDERM Study in…